Compare Eli Lilly And Co (LLY) vs Williams Companies Inc (WMB) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Williams Companies (WMB) trades at $72.67, up 1.69% today, with strong analyst support (79% buy ratings) and a consensus price target of $87.27. The stock shows bullish technical signals with support at $72 and resistance at $73. Fundamentally, WMB delivered $11.95B revenue in 2025 with 25.18% net income margin, though recent quarterly earnings were mixed with one beat and two misses. The company benefits from stable fee-based revenues in the midstream energy sector.

WMB presents a compelling opportunity with dividend growth potential and exposure to rising natural gas demand from data centers. However, investors face risks from energy market volatility and high debt levels. The stock trades at a premium valuation (P/E 28.82) but offers 3% dividend yield with consistent payout increases. Near-term catalysts include Q3 earnings and AI-driven power demand growth.